Core Viewpoint - Fosun Pharma's subsidiary, Hanhui, has received FDA approval for two biosimilar products, denosumab-nxxp, which are similar to the original PROLIA® and XGEVA® [1] Group 1: Product Approval - The FDA has approved the marketing applications for BILDYOS® (denosumab-nxxp) at a concentration of 60mg/mL and BILPREVDA® (denosumab-nxxp) at a concentration of 120mg/1.7mL [1] - The approval covers all indications for the original products that have been approved in the United States [1]